Ipsen

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…

This study looks at how well the drug cabozantinib works and how safe it is for adults with neuroendocrine tumors (NETs) that have continued to grow after at least one prior treatment. About 150 participants in Germany and Austria will be followed during their routine care. Docto…

This study tests a new drug called IPN60300 in adults with advanced solid tumors that have spread or not responded to standard treatments. The goal is to find the best dose and check if it is safe and shrinks tumors. All participants get the drug by injection, and the study invol…

This study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …

This study follows 30 people with Alagille syndrome who are taking odevixibat (Bylvay) in their daily lives. The goal is to see if the drug helps them avoid serious surgeries like liver transplant or bile duct repair over the long term. Researchers will also track weight, height,…

This Phase 3 trial tests elafibranor, a daily pill, against a placebo in 276 adults with primary biliary cholangitis (PBC) and cirrhosis. The goal is to see if elafibranor can prevent disease worsening, such as liver failure or death, over up to 3.5 years. Researchers will also m…

This Phase 3 study tests whether the drug elafibranor can slow liver damage in adults with primary sclerosing cholangitis (PSC), a rare disease that scars the bile ducts. About 350 participants will receive either elafibranor or a placebo daily for several years. The main goal is…

This study follows about 424 people with primary biliary cholangitis (PBC) who are taking elafibranor as part of their normal care. Researchers will track how well the drug controls liver damage and symptoms like itching over 5 years. The goal is to see if elafibranor works safel…

This study will follow 30 people with Alagille syndrome who are taking odevixibat in their daily lives. The goal is to see how safe the drug is over the long term by tracking any side effects. It is not testing if the drug works, but rather monitoring its real-world safety.

This registry will follow 10 people with progressive familial intrahepatic cholestasis (PFIC) in South Korea who are taking odevixibat (Bylvay). The goal is to see how safe and effective the drug is over the long term in real-world use. Researchers will track side effects and how…

This registry will follow 20 people in China with progressive familial intrahepatic cholestasis (PFIC) who are taking odevixibat (Bylvay) as part of their normal care. The goal is to see how safe the drug is over the long term and how well it controls symptoms like severe itching…

This Phase 3 trial tests whether a single injection of corabotase (IPN10200) can safely reduce the appearance of moderate-to-severe frown lines between the eyebrows in adults. Participants will receive either the study drug or a placebo, then be followed for up to a year to see i…

This phase 3 study tests an injection called IPN10200 for moderate to severe frown lines (the wrinkles between your eyebrows). About 1,300 adults will receive either the active treatment or a placebo, and some may get up to 4 treatment cycles over nearly two years. The goal is to…

This study tests a new drug, IPN10200, for adults with cervical dystonia—a condition causing painful neck muscle spasms. Current treatments last about 3 months, but IPN10200 is designed to work longer. Around 132 participants will receive either the drug or a placebo injection, a…

This study tests a new medicine called IPN10200 for adults with arm muscle stiffness (spasticity) after a stroke or traumatic brain injury. The goal is to find the safest and most effective dose to reduce stiffness and improve movement. About 240 participants will receive either …

This registry study follows about 100 people with FOP, a rare disease where soft tissue turns to bone. Some participants take palovarotene (an approved treatment), while others do not. Researchers will track side effects, flare-ups, and daily function over time to see how well th…

This study follows people who took elafibranor shortly before or during pregnancy to see if it affects the baby or mother. Researchers will collect information from medical records and safety reports over about 10 years. No extra tests or treatments are required—only routine care…

This study follows up to 20 people of any age who took the drug odevixibat while pregnant or breastfeeding. Researchers will collect routine medical data to see if the drug is linked to birth defects, pregnancy complications, or harm to the baby. No extra tests or visits are requ…